China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from the Center for Drug Evaluation (CDE) to conduct a clinical study for SYS6002, an antibody-drug conjugate (ADC) developed in-house by its subsidiary CSPC Jushi Biopharmaceutical Co., Ltd. The intended indication for SYS6002 is advanced solid tumors.
SYS6002: Mechanism of Action and Preclinical Results
SYS6002 is a monoclonal ADC designed to bind to specific undisclosed receptors on the surface of tumor cells. The drug enters cells through endocytosis, releases toxins, and kills tumor cells. Preclinical studies have demonstrated that SYS6002 exhibits good anti-tumor effects across various types of cancer, positioning it as a promising candidate for the treatment of advanced solid tumors.
Future Outlook
With CDE approval in hand, CSPC is set to advance SYS6002 into clinical trials, marking a significant milestone in the development of innovative treatments for advanced solid tumors. The company aims to leverage the ADC’s targeted mechanism of action to improve outcomes for patients with these challenging cancers.-Fineline Info & Tech
